EU Approves New Alzheimer's Drug After Initial Resistance

2 hours ago

EU Approves New Alzheimer's Drug After Initial Resistance
Generated image for illustrative purposes:

7 Highlights

  • EU approves Alzheimer's drug Leqembi after initial rejection.
  • Lecanemab slows cognitive decline by targeting amyloid plaques.
    • EMA resolved risk concerns with Leqembi's careful monitoring.
    • Leqembi is given biweekly via intravenous drip in specific cases.
    • Restrictions apply to ApoE4 gene carriers using Leqembi.
    • UK NHS excludes Leqembi over cost issues despite US approval.
    • Alzheimer's impacts 7.8M people in the EU; monitoring is vital.
0 Comments

0 Comments

Be the first to comment

Add your thoughts and get the conversation going.

Related Articles

Explore Your Interests

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access
Personalized Feed
Full Experience
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.